Conflict of interest statement: Conflicts of interest disclosure statement: 
E.Y.R. reports research support from Bayer. M.L.J. reports research funds to her 
institution from Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and 
Company (hereafter referred to as Loxo Oncology); AbbVie; Acerta; Adaptimmune; 
Apexigen; Array BioPharma; AstraZeneca; Atreca; BeiGene; Birdie; Boehringer 
Ingelheim; Checkpoint Therapeutics; Corvus Pharmaceuticals; CytomX; Daiichi 
Sankyo; Dynavax; Eli Lilly and Company; EMD Serono; Genentech/Roche; Genmab; 
Genocea Biosciences; GlaxoSmithKline; Gritstone Oncology; Guardant Health; 
Hengrui Therapeutics; Immunocore; Incyte; Janssen; Jounce Therapeutics; Kadmon 
Pharmaceuticals; Lycera; Merck; Mirati Therapeutics; Neovia Oncology; Novartis; 
OncoMed Pharmaceuticals; Pfizer; Regeneron Pharmaceuticals; Sanofi; Shattuck 
Labs; Stem CentRx; Syndax Pharmaceuticals; Takeda Pharmaceuticals; Tarveda; 
University of Michigan; WindMIL; TCR2 Therapeutics; Arcus Biosciences; Ribon 
Therapeutics; and Amgen. M.L.J. also reports consulting/advisory roles through 
her institution for AbbVie, Achilles Therapeutics, AstraZeneca, Atreca, 
Boehringer Ingelheim, Calithera Biosciences, Genentech, GlaxoSmithKline, 
Gritstone Oncology, Guardant Health, Incyte, Janssen, Eli Lilly and Company, 
Loxo Oncology, Merck, Mirati Therapeutics, Novartis, Pfizer, Ribon Therapeutics, 
Sanofi, and Association of Community Cancer Centers; fees for 
food/beverage/travel from Abbvie, Astellas, AstraZeneca, Boehringer Ingelheim, 
Clovis, Daiichi Sankyo, EMD Serono, Bristol Myers Squibb, Exelixis, 
Genentech/Roche, Incyte, Merck, Pfizer, Sysmex Inostics, Vapotherm, Janssen, Eli 
Lilly and Company, Novartis, and Sanofi; and Contract Lobbyist roles of her 
spouse for Astellas and Otsuka Pharmaceuticals. S.E.C. reports no conflicts of 
interest. R.S. reports research funding from Loxo Oncology, Helsinn Healthcare, 
Merus, and Elevation Oncology. J.F.K. is an employee of Loxo Oncology. J.S., 
A.A.B., M.A.D., and E.G. report no conflicts of interest. E.V.I. reports being 
an inventor on a pending patent related to manipulating, culturing, and 
evaluating tumor organotypic spheroids in 3D microfluidic devices. D.N.H. is an 
employee of Loxo Oncology. E.M.K., M. Lin, and M.S.D.M. report no conflicts of 
interest. B.C.N. and E.A.O. are employees of Loxo Oncology. J.E.S. and M.V. 
report no conflicts of interest. K.E. is an employee and stockholder of Loxo 
Oncology. J.F.H. reports a research grant from Eli Lilly and Company and an 
honorarium from Illumina. B.T.L. reports two pending institutional patents at 
Memorial Sloan Kettering Cancer Center (US62/685,057, US62/514,661); 
consultant/advisory board member roles for Roche/Genentech, Biosceptre 
International, Thermo Fisher Scientific, Mersana Therapeutics, Hengrui 
Therapeutics, Guardant Health, Eli Lilly and Company; and research funds to his 
institution from Roche/Genentech, Daiichi Sankyo, Hengrui Therapeutics, 
Illumina, Guardant Health, BioMed Valley Discoveries, AstraZeneca, GRAIL, MORE 
Health, Amgen, and Eli Lilly and Company. L.M.S. reports consulting fees from 
EMD Serono, scientific advisory board roles for Loxo Oncology and Foghorn 
Therapeutics, and honorarium from Astra Zeneca. B.S.T. reports honoraria and 
research funding from Genentech and discovery board activities for Boehringer 
Ingelheim and Loxo Oncology; all stated activities were outside of the work 
described herein. M. Ladanyi reports ad hoc advisory board roles for Eli Lilly 
and Company and Loxo Oncology, and research support from Helsinn Healthcare and 
Loxo Oncology. P.A.J. reports consulting fees from AstraZeneca, 
Boehringer-Ingelheim, Pfizer, Roche/Genentech, Takeda Oncology, ACEA 
Biosciences, Eli Lilly and Company, Araxes Pharma, Ignyta, Mirati Therapeutics, 
Novartis, Loxo Oncology, Daiichi Sankyo, Sanofi Oncology, Voronoi, SFJ 
Pharmaceuticals and Biocartis; receiving post-marketing royalties from DFCI 
owned intellectual property on EGFR mutations licensed to Lab Corp; sponsored 
research agreements with AstraZeneca, Daichi-Sankyo, PUMA, Boehringer Ingelheim, 
Eli Lilly and Company, Revolution Medicines and Astellas Pharmaceuticals; and 
stock ownership in Loxo Oncology and Gatekeeper Pharmaceuticals. S.M.R., a 
former employee of Loxo Oncology, was employed by Loxo Oncology at the time of 
this work. A.E.D. reports consulting/advisory roles for Ignyta, Loxo Oncology, 
TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech/Roche, 
Helsinn Therapeutics, BeiGene, Hengrui Therapeutics, Exelixis, Bayer, Tyra 
Biosciences, Verastem, Takeda/Millennium, BerGenBio, MORE Health, Eli Lilly and 
Company, and Verastem; royalties for Pocket Oncology; honoraria from Medscape, 
OncLive, PeerVoice, Physician’s Education Resource, Targeted Oncology, MORE 
Health, Research to Practice, Foundation Medicine, and Peerview; and research 
funding from Foundation Medicine. G.R.O. reports consulting fees from Abbvie, 
AstraZeneca, Blueprint, Dropworks, GRAIL, Janssen, Illumina, Inivata, Loxo 
Oncology, Sysmex, and Takeda; and honoraria from Foundation Medicine and 
Guardant.